Christine Willmore Email

Quality Assurance Manager . NovaBay Pharmaceuticals

Current Roles

Employees:
71
Revenue:
$7.1M
About
NovaBay Pharmaceuticals $NBY is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. NovaBay has two distinct product categories: the NEUTROX family of products, led by AVENOVA for the eye care market, NEUTROPHASE® for wound care, and CELLERX for the dermatology market; and AGANOCIDE® compounds, led by AURICLOSENE. NovaBay is commercializing AVENOVA, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction also known as dry eye syndrome. These difficult-to-manage conditions affect approximately 30 million Americans, with an annual market potential that NovaBay estimates at $500 million. NovaBay is gaining market traction with AVENOVA through its 35-medical direct sales representatives under veteran leadership. AVENOVA is available for order in 90% of all pharmacies across the U.S. through distribution agreements with AmerisourceBergen, Cardinal Health and McKesson. www.novabay.com. www.Avenova.com www.neutrophase.com www.celerex.com
NovaBay Pharmaceuticals Address
2000 Powell Street
Emeryville, CA
United States
NovaBay Pharmaceuticals Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.